Fibrinolytic Enzyme - An Overview
- PMID: 34983344
- DOI: 10.2174/1389201023666220104143113
Fibrinolytic Enzyme - An Overview
Abstract
Cardiovascular diseases, like coronary heart disease or artery disorders (arteriosclerosis, including artery solidification), heart failure (myocardial infarction), arrhythmias, congestive heart condition, stroke, elevated vital signs (hypertension), rheumatic heart disorder, and other circulatory system dysfunctions are the most common causes of death worldwide. Cardiovascular disorders are treated with stenting, coronary bypass surgery grafting, anticoagulants, antiplatelet agents, and other pharmacological and surgical procedures; however, these have limitations due to their adverse effects. Fibrinolytic agents degrade fibrin through enzymatic and biochemical processes. There are various enzymes that are currently used as a treatment for CVDs, like streptokinase, nattokinase, staphylokinase, urokinase, etc. These enzymes are derived from various sources, like bacteria, fungi, algae, marine organisms, plants, snakes, and other organisms. This review deals with the fibrinolytic enzymes, their mechanisms, sources, and their therapeutic potential.
Keywords: Enzyme; biocatalyst; cardiovascular disease; fibrinolysis; fibrinolytic agents; therapeutic potential.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi.Biotechnol Prog. 2014 May-Jun;30(3):656-72. doi: 10.1002/btpr.1918. Epub 2014 May 7. Biotechnol Prog. 2014. PMID: 24799449 Review.
-
New developments in thrombolytic therapy.Adv Exp Med Biol. 1990;281:333-54. Adv Exp Med Biol. 1990. PMID: 2129372 Review.
-
Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD002312. doi: 10.1002/14651858.CD002312.pub4. Cochrane Database Syst Rev. 2019. PMID: 31684683 Free PMC article.
-
New developments in thrombolytic therapy.Thromb Res Suppl. 1990;10:105-31. doi: 10.1016/0049-3848(90)90384-o. Thromb Res Suppl. 1990. PMID: 2180114 Review.
-
Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.Eur Heart J. 1996 Feb;17(2):230-6. doi: 10.1093/oxfordjournals.eurheartj.a014839. Eur Heart J. 1996. PMID: 8732376 Clinical Trial.
Cited by
-
Production of Nattokinase from Bacillus amyloliquefaciens MRS18: A Bacterial Strain Isolated from Fermented Beans.Cardiovasc Hematol Agents Med Chem. 2024;22(2):223-229. doi: 10.2174/0118715257275639231219054353. Cardiovasc Hematol Agents Med Chem. 2024. PMID: 38173058
-
Development of an Ultrasensitive Competitive Double-Enzyme Cascade Fluorescence Signal Amplification Method for Factor XIa Inhibitor Screening.Anal Chem. 2024 Oct 8;96(40):16091-16098. doi: 10.1021/acs.analchem.4c04369. Epub 2024 Sep 28. Anal Chem. 2024. PMID: 39340422
-
Purification and Characterization of a Novel Fibrinolytic Enzyme from Marine Bacterium Bacillus sp. S-3685 Isolated from the South China Sea.Mar Drugs. 2024 Jun 10;22(6):267. doi: 10.3390/md22060267. Mar Drugs. 2024. PMID: 38921578 Free PMC article.
-
Unveiling the Potent Fibrino(geno)lytic, Anticoagulant, and Antithrombotic Effects of Papain, a Cysteine Protease from Carica papaya Latex Using κ-Carrageenan Rat Tail Thrombosis Model.Int J Mol Sci. 2023 Nov 26;24(23):16770. doi: 10.3390/ijms242316770. Int J Mol Sci. 2023. PMID: 38069092 Free PMC article.
-
Purification and Biochemical Characterization of a Novel Fibrinolytic Enzyme from Culture Supernatant of Coprinus comatus.Foods. 2024 Apr 23;13(9):1292. doi: 10.3390/foods13091292. Foods. 2024. PMID: 38731663 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical